Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSL402-XEC
- Development stage
- Unknown
- Lead developer
- CSL Seqirus
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CSL402-XEC is a self-amplifying mRNA (sa-mRNA) vaccine candidate developed for the prevention of COVID-19, specifically targeting the SARS-CoV-2 XEC variant. It is part of a next-generation vaccine platform developed by Arcturus Therapeutics in collaboration with CSL and Meiji Seika Pharma. The sa-mRNA technology (STARR) incorporates a viral replicase that allows the mRNA to replicate itself once inside the host cell, potentially enabling lower doses and more durable immune responses compared to conventional mRNA vaccines. CSL402-XEC is delivered using the LUNAR lipid nanoparticle (LNP) system. In Japan, Meiji Seika Pharma is conducting Phase 3 clinical trials to evaluate its safety and immunogenicity as a booster dose in individuals aged 12 years and older.
- Other names
- self-amplifying mRNA COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on CSL402-XEC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSL402-XEC.